Devalingam Mahalingam

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 11

Top Topics

Chemotherapy Induced

Prognostic Factors

Top Venues

Communications medicine

Cancer research communications

JCO precision oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications 4 (7) (2024)
Jian Jenny Chen, Melanie Y Vincent, Dale Shepard, David Peereboom, Devalingam Mahalingam, James Battiste, Manish R Patel, Dejan Juric, Patrick Y Wen, Andrea J Bullock, Jennifer Eva Selfridge, Shubham Pant, Joyce Liu, Wendy Li, Susanne Fyfe, Suming Wang, Victor Zota, James Mahoney, Randolph S Watnick, Michael Cieslewicz, Jing Watnick
Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors. Communications medicine 4 (1) (2024)
Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications 4 (7) (2024)
Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications 4 (7) (2024)
Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications (2024)
Jian Jenny Chen, Melanie Y Vincent, Dale Shepard, David Peereboom, Devalingam Mahalingam, James Battiste, Manish R Patel, Dejan Juric, Patrick Y Wen, Andrea J Bullock, Jennifer Eva Selfridge, Shubham Pant, Joyce Liu, Wendy Li, Susanne Fyfe, Suming Wang, Victor Zota, James Mahoney, Randolph S Watnick, Michael Cieslewicz, Jing Watnick
Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors. Communications medicine 4 (1) (2024)
Devalingam Mahalingam, Wael Harb, Amita Patnaik, Andrea J Bullock, Randolph S Watnick, Melanie Y Vincent, Jian Jenny Chen, Suming Wang, Harold Pestana, Judy Chao, James Mahoney, Michael Cieslewicz, Jing Watnick
First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors. Communications medicine 4 (1) (2024)
Devalingam Mahalingam, Wael Harb, Amita Patnaik, Andrea J Bullock, Randolph S Watnick, Melanie Y Vincent, Jian Jenny Chen, Suming Wang, Harold Pestana, Judy Chao, James Mahoney, Michael Cieslewicz, Jing Watnick
First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors. Communications medicine 4 (1) (2024)
Jian Jenny Chen, Melanie Y Vincent, Dale Shepard, David Peereboom, Devalingam Mahalingam, James Battiste, Manish R Patel, Dejan Juric, Patrick Y Wen, Andrea J Bullock, Jennifer Eva Selfridge, Shubham Pant, Joyce Liu, Wendy Li, Susanne Fyfe, Suming Wang, Victor Zota, James Mahoney, Randolph S Watnick, Michael Cieslewicz, Jing Watnick
Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors. Communications medicine 4 (1) (2024)
Benedito Arruda Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, Anwaar Saeed, Howard Safran, Wen Wee Ma, Andrew L Coveler, Steven Francis Powell, Bruno R Bastos, Elizabeth J Davis, Vaibhav Sahai, William Mikrut, James Longstreth, Sheri Smith, Taylor M Weiskittel, Hu Li, Brittany A Borden, Robert Donald Harvey, Solmaz Sahebjam, Andres Cervantes, Austin Koukol, Andrew P Mazar, Neeltje Steeghs, Razelle Kurzrock, Francis J Giles, Pamela N Munster
Phase 1 study of Elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, as monotherapy or combined with chemotherapy in patients with advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Lorenzo Gerratana, Michael Movarek, Firas H Wehbe, Neelima Katam, Devalingam Mahalingam, Jeannine Donahue, Ami Shah, Young Kwang Chae, Mary F Mulcahy, Dean Tsarwhas, Victoria Villaflor, Aparna Kalyan, Maha H A Hussain, Jyoti D Patel, Sunandana Chandra, Leonidas C Platanias, William J Gradishar, Massimo Cristofanilli, Amir Behdad
Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience. JCO precision oncology 6 (2022)